Tesamorelin
Tesamorelin is a growth hormone-releasing hormone analogue studied in endocrine and metabolic research. It is distinct from the shorter GRF fragment associated with sermorelin.
Reviewed September 2026
- Residues
- 44. verified: 44 peptide-chain residues; the N-terminal hexenoyl substituent is not a residue.
- Average mass
- 5,135.9 Da. verified: Sponsor-label molecular weight for tesamorelin free-base equivalent, C221H366N72O67S, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 44 |
|---|---|
| Average mass | 5,135.9 Da |
| pI | Not established |
| Research area | Growth hormone |
|---|
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Tesamorelin free-base equivalent: 44-residue human GRF chain with N-terminal hexenoyl group. Acetate content is not included and the sold preparation is not identified by this value. Reference only, not a sold-lot measurement.
- Residues: 44 (verified). 44 peptide-chain residues; the N-terminal hexenoyl substituent is not a residue. Residues source 1
- Average mass: 5,135.9 Da (verified). Sponsor-label molecular weight for tesamorelin free-base equivalent, C221H366N72O67S, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement. Average mass source 1 Average mass source 2
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Tesamorelin. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Effect of tesamorelin on visceral fat and liver fat: randomized clinical trial. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Tesamorelin
Identity and context
The relevant biological pathway is stimulation of endogenous growth hormone secretion through a releasing-hormone analogue. This is different from supplying growth hormone itself and from the secretagogue class represented by ipamorelin. Those distinctions matter when choosing a comparator in an experiment.
Reference classification
Modified peptide. The linked catalogue product is Tesamorelin. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the complete analogue structure and chemical form. A generic GHRH sequence, or the sequence of sermorelin, would not be an adequate identity record for tesamorelin.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | A randomized placebo-controlled study examined visceral and liver fat in antiretroviral-treated people with HIV and abdominal fat accumulation. It reported changes in those endpoints and monitored glucose metabolism. The narrowly defined population is part of the finding, not an incidental detail that can be removed from the result. | Source context |
| What cannot be inferred | This trial does not establish a general fat-loss effect in all populations, nor does it establish equivalence of a research catalogue preparation to the study drug. The listed product is not given a clinical indication by this reference. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Effect of tesamorelin on visceral fat and liver fat: randomized clinical trialPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.